These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 21807507)
21. Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors. Li CY; Li QS; Yan L; Sun XG; Wei R; Gong HB; Zhu HL Bioorg Med Chem; 2012 Jun; 20(12):3746-55. PubMed ID: 22583669 [TBL] [Abstract][Full Text] [Related]
22. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors. Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678 [TBL] [Abstract][Full Text] [Related]
23. Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. Stellwagen JC; Adjabeng GM; Arnone MR; Dickerson SH; Han C; Hornberger KR; King AJ; Mook RA; Petrov KG; Rheault TR; Rominger CM; Rossanese OW; Smitheman KN; Waterson AG; Uehling DE Bioorg Med Chem Lett; 2011 Aug; 21(15):4436-40. PubMed ID: 21733693 [TBL] [Abstract][Full Text] [Related]
24. Discovery and optimization of pyrazoline compounds as B-Raf inhibitors. Duffey MO; Adams R; Blackburn C; Chau RW; Chen S; Galvin KM; Garcia K; Gould AE; Greenspan PD; Harrison S; Huang SC; Kim MS; Kulkarni B; Langston S; Liu JX; Ma LT; Menon S; Nagayoshi M; Rowland RS; Vos TJ; Xu T; Yang JJ; Yu S; Zhang Q Bioorg Med Chem Lett; 2010 Aug; 20(16):4800-4. PubMed ID: 20634068 [TBL] [Abstract][Full Text] [Related]
25. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors. Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737 [TBL] [Abstract][Full Text] [Related]
26. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells. Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204 [TBL] [Abstract][Full Text] [Related]
27. Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents. Zuo SJ; Zhang S; Mao S; Xie XX; Xiao X; Xin MH; Xuan W; He YY; Cao YX; Zhang SQ Bioorg Med Chem; 2016 Jan; 24(2):179-90. PubMed ID: 26706113 [TBL] [Abstract][Full Text] [Related]
28. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors. Packard GK; Papa P; Riggs JR; Erdman P; Tehrani L; Robinson D; Harris R; Shevlin G; Perrin-Ninkovic S; Hilgraf R; McCarrick MA; Tran T; Fleming Y; Bai A; Richardson S; Katz J; Tang Y; Leisten J; Moghaddam M; Cathers B; Zhu D; Sakata S Bioorg Med Chem Lett; 2012 Jan; 22(1):747-52. PubMed ID: 22137342 [TBL] [Abstract][Full Text] [Related]
29. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties. Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124 [TBL] [Abstract][Full Text] [Related]
30. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. Chao Q; Sprankle KG; Grotzfeld RM; Lai AG; Carter TA; Velasco AM; Gunawardane RN; Cramer MD; Gardner MF; James J; Zarrinkar PP; Patel HK; Bhagwat SS J Med Chem; 2009 Dec; 52(23):7808-16. PubMed ID: 19754199 [TBL] [Abstract][Full Text] [Related]
31. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase. Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962 [TBL] [Abstract][Full Text] [Related]
32. Entry into a new class of protein kinase inhibitors by pseudo ring design. Furet P; Caravatti G; Guagnano V; Lang M; Meyer T; Schoepfer J Bioorg Med Chem Lett; 2008 Feb; 18(3):897-900. PubMed ID: 18248988 [TBL] [Abstract][Full Text] [Related]